Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
GreenMatter Biotech Inc. is a materials science and biotechnology company dedicated to developing plant-based, biodegradable alternatives to traditional single-use plastics. Headquartered in Dallas, Texas, the company utilizes a proprietary technology platform to engineer regenerative materials that offer high durability during use while ensuring complete biodegradability in soil after disposal. In April 2026, GreenMatter Biotech completed a strategic merger with Great American Food Chain, Inc. (OTC: GAMN), marking its transition into the public markets. The company reported $2.5 million in revenue for the 2025 fiscal year, driven by growing demand for sustainable solutions in consumer products and medical packaging. Led by CEO Joe H. Wicker Jr., GreenMatter Biotech aims to lead the transition toward a circular economy by providing scalable, eco-friendly material alternatives.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on GreenMatter Biotech.